Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
In March, the FDA approved DexCom Inc's (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).
三月份，美国食品和药物管理局批准了德康医疗公司（纳斯达克股票代码: DXCM）的Stelo葡萄糖生物传感器系统，作为第一个非处方（OTC）连续葡萄糖监测器（CGM）。
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
德康医疗的Stelo葡萄糖生物传感器系统是一种集成CGM（iCGM），适用于18岁及以上不使用胰岛素的人群。
On Monday, DexCom announced Stelo is now available for purchase without a prescription at Stelo.com.
周一，德康医疗宣布Stelo现在可在Stelo.com上无需处方购买。
Stelo is a small biosensor worn on the back of the upper arm.
Stelo是一个小型生物传感器，佩戴在上臂背面。
It is specifically designed to provide the 125 million Americans with Type 2 diabetes who are not using insulin and those with prediabetes with personalized glucose insights sent directly to their smartphones.
它专门设计为向1,2500万不使用胰岛素的美国2型糖尿病患者和有糖尿病前期的人提供个性化葡萄糖洞察，直接发送至他们的智能手机。
These insights reveal how food, exercise, and sleep can affect glucose—all without painful fingersticks.
这些洞察揭示了食物、运动和睡眠如何影响葡萄糖，而无需痛苦的戳指血检。
Also Read: Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers.
另请阅读：雅培公司积极推广新葡萄糖监测器，瞄准健康意识消费者。
Users can buy a one-month supply online for $99 (for a single pack of two sensors (total wear time up to 30 days) or sign up for an ongoing subscription at $89 a month.
用户可以在网上以99美元购买一个月的供应（两个传感器的单独包装（总佩戴时间长达30天），或者以89美元/月的价格订阅连续购买。
In June, the FDA approved two new over-the-counter continuous glucose monitoring (CGM) systems from Abbott Laboratories (NYSE:ABT): Lingo and Libre Rio. These systems are based on Abbott's FreeStyle Libre technology, which is now used by about 6 million people globally.
六月份，美国食品和药物管理局（FDA）批准了雅培实验室（纽交所: ABT）推出的两款新的可购买的连续葡萄糖监测（CGM）系统：Lingo和Libre Rio。这些系统基于雅培的FreeStyle Libre技术，目前全球约有600万人使用。
Reuters noted that Lingo has been available in Britain since January for $152-$190 (120-150 pounds) per month.
路透社指出，Lingo自今年1月起在英国上市，每月售价为152-190美元（120-150英镑）。
Jake Leach, chief operating officer at Dexcom, told CNBC in an interview that Dexcom is working with Amazon to fulfill Stelo deliveries.
Dexcom首席运营官杰克·利奇在接受CNBC采访时表示，Dexcom正在与亚马逊合作，完成Stelo的交付。
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, CNBC noted.
Dexcom表示，患者还可以选择使用自己的灵活支出账户和医疗储蓄账户来支付Stelo，CNBC指出。
Stelo is a small, gray device worn on the upper arm, about the size of a quarter and half an inch thick, with a 15-day lifespan before needing replacement. It wirelessly transmits data to a smartphone app, where users specify whether they have Type 2 diabetes, prediabetes, or neither. This information sets a "Target Range" for maintaining optimal glucose levels.
Stelo是一款佩戴在上臂上的小巧灰色装置，大约是一个25美分硬币的大小，厚度约半英寸，使用寿命为15天，在需要更换前无线传输数据到智能手机应用程序，用户可以指定是否患有2型糖尿病、糖尿病前期或两者都没有。这些信息设置了维持血糖水平的“目标范围”。
Price Action: DXCM stock is up 0.48% at $74.43 at last check Monday.
股票价格表现: 德康医疗股票最近的检查显示涨幅为0.48%，报74.43美元。
- Baker Hughes Says US Oil And Gas Rig Count Declines For Second Week: Report
- baker hughes表示，美国石油和燃料币钻井数量连续第二周下降。
Photo: Shutterstock
Photo: shutterstock